Trials / Unknown
UnknownNCT05390476
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 126 (estimated)
- Sponsor
- wang shusen · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to explore and evaluate the efficacy of tucidinostat combined with metronomic capecitabine in the treatment of metastatic triple-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | 500mg orally three times a day (continuously) |
| DRUG | Tucidinostat | 20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration) |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2024-02-01
- Completion
- 2024-12-01
- First posted
- 2022-05-25
- Last updated
- 2022-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05390476. Inclusion in this directory is not an endorsement.